{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:54:12Z","timestamp":1748361252813},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Gregorio Mara\u00f1\u00f3n Hospital in Madrid"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Low-molecular-weight heparins (LMWHs) are easily dialysable with high-flow membranes; however, it is not clear whether the LMWH dose should be adjusted according to the membrane type and dialysis technique. This study aimed to evaluate the influence of the dialyser on anticoagulation of the extracorporeal dialysis circuit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Thirteen patients received the same dose of LMWH through the arterial port via three dialysis techniques: high-flux haemodialysis (HF-HD), online haemodiafiltration (HDF) and expanded haemodialysis (HDx). All dialysis was performed under similar conditions: duration, 4\u2009h; blood flow, 400\u2009mL\/min; and dialysate flow, 500\u2009mL\/min. Antifactor Xa (aXa) activity and activated partial thromboplastin time (APTT) were measured before and after the dialysis. Clotting time of the vascular access site after haemodialysis, visual clotting score of the dialyser and any complications with the extracorporeal circuit or bleeding were registered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Post-dialysis aXa activity in HF-HD (0.26\u2009\u00b1\u20090.02\u2009U\/mL) was significantly different from that in HDF (0.21\u2009\u00b1\u20090.02\u2009U\/mL, P\u2009=\u20090.024), and there was a trend in HDx (0.22\u2009\u00b1\u20090.01\u2009U\/mL, P\u2009=\u20090.05). APTT post-dialysis in HF-HD (30.5\u2009\u00b1\u20090.7\u2009s) was significantly different from that in HDx (28.2\u2009\u00b1\u20090.64\u2009s, P\u2009=\u20090.009) and HDF (28.8\u2009\u00b1\u20090.73\u2009s, P\u2009=\u20090.009).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>AXa activity in HDF was significantly lower than that in HF-HD, possibly because of more losses of LMWH through the dialyser. Given the higher anticoagulant loss in HDF and probably in HDx than in HF-HD, the enoxaparin dose administered may be adjusted according to the dialysis technique.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfaa057","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T04:58:25Z","timestamp":1584593905000},"page":"1120-1125","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration"],"prefix":"10.1093","volume":"14","author":[{"given":"Alba","family":"Santos","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitario del Vinalop\u00f3, Elche, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Mac\u00edas","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Vega","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Abad","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Linares","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Aragoncillo","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas","family":"Cruzado","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario de Elche, Elche, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Pascual","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Goicoechea","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"L\u00f3pez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"2021060310392973300_sfaa057-B1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrneph.2011.88","article-title":"What are the anticoagulation options for intermittent hemodialysis?","volume":"7","author":"Davenport","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2021060310392973300_sfaa057-B2","first-page":"171","article-title":"Anticoagulation options for intermittent hemodialysis","volume":"58","author":"Davenport","year":"2006","journal-title":"Minerva Urol Nefrol"},{"key":"2021060310392973300_sfaa057-B3","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1111\/hdi.12086","article-title":"The rationale for the use of low molecular weight heparin for hemodialysis treatments","volume":"17","author":"Davenport","year":"2013","journal-title":"Hemodial Int"},{"key":"2021060310392973300_sfaa057-B4","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1111\/j.1440-1797.2005.00464_1.x","article-title":"The CARI guidelines. Dialyisis adequacy (HD) guidelines","volume":"10 (Suppl 4","author":"Kerr","year":"2005","journal-title":"Nephrology (Carlton)"},{"key":"2021060310392973300_sfaa057-B5","first-page":"63","article-title":"Section V: Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system","volume":"17 (Suppl 7","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2021060310392973300_sfaa057-B6","first-page":"143","article-title":"Spanish study of anticoagulation in haemodialysis","volume":"32","author":"Herrero-Calvo","year":"2012","journal-title":"Nefrologia"},{"key":"2021060310392973300_sfaa057-B7","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1097\/01.ASN.0000145014.80714.35","article-title":"Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials","volume":"15","author":"Lim","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2021060310392973300_sfaa057-B8","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.7717\/peerj.835","article-title":"Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis","volume":"3","author":"Palamaner Subash Shantha","year":"2015","journal-title":"Peer J"},{"key":"2021060310392973300_sfaa057-B9","doi-asserted-by":"crossref","first-page":"c107","DOI":"10.1159\/000158561","article-title":"Comparison of tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity","volume":"110","author":"Bramham","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"2021060310392973300_sfaa057-B10","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/ndt\/14.8.1943","article-title":"A single dose of dalteparin effectively prevents clotting during haemodialysis","volume":"14","author":"Sagedal","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"2021060310392973300_sfaa057-B11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1525-139X.2000.00052.x","article-title":"Anticoagulation for intermittent hemodialysis","volume":"13","author":"Ouseph","year":"2000","journal-title":"Semin Dial"},{"key":"2021060310392973300_sfaa057-B12","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/ajkd.2002.36331","article-title":"Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients","volume":"40","author":"Polkinghorne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2021060310392973300_sfaa057-B13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000348830","article-title":"Dalteparin dosing in high-flux haemodialysis and haemodiafiltration","volume":"122","author":"Sridharan","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2021060310392973300_sfaa057-B14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1542-4758.2009.00336.x","article-title":"The anticoagulant activity of enoxaparin sodium during on-line hemodiafiltration and conventional hemodialysis","volume":"13","author":"Sombolos","year":"2009","journal-title":"Hem Int"},{"key":"2021060310392973300_sfaa057-B15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0272-6386(04)00827-3","article-title":"Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin and iron sucrosa during dialysis","volume":"44","author":"McMahon","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2021060310392973300_sfaa057-B16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000107241","article-title":"Online hemodiafiltration. Technical options and best clinical practices","volume":"158","author":"Canaud","year":"2007","journal-title":"Contrib Nephrol"},{"key":"2021060310392973300_sfaa057-B17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000493910","article-title":"Is expanded hemodialysis an option to online hemodiafiltration for small and middle sized molecules clearance?","volume":"47","author":"Reque","year":"2019","journal-title":"Blood Purif"},{"key":"2021060310392973300_sfaa057-B18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/ckj\/sfy097","article-title":"Middle molecule elimination in expanded haemodialysis: only convective transport?","volume":"12","author":"Mac\u00edas","year":"2018","journal-title":"Clin Kidney J"},{"key":"2021060310392973300_sfaa057-B19","doi-asserted-by":"crossref","first-page":"18448","DOI":"10.1038\/srep18448","article-title":"MCO membranes: enhanced selectivity in high-flux","volume":"5","author":"Boschetti-de-Fierro","year":"2015","journal-title":"Sci Rep"},{"key":"2021060310392973300_sfaa057-B20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000479263","article-title":"Expanded hemodialysis therapy: prescription and delivery","volume":"191","author":"Heyne","year":"2017","journal-title":"Contrib Nephrol"},{"key":"2021060310392973300_sfaa057-B21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ndt\/gfs530","article-title":"Online haemodiafiltration: definition, dose quantification and safety revisited","volume":"28","author":"Tattersall","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2021060310392973300_sfaa057-B22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1440-1797.2009.01135.x","article-title":"Review article: low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments","volume":"14","author":"Davenport","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"2021060310392973300_sfaa057-B23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000046675","article-title":"Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center","volume":"22","author":"Lord","year":"2002","journal-title":"Am J Nephrol"},{"key":"2021060310392973300_sfaa057-B24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2369-13-50","article-title":"A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis \u2013 the membrane study","volume":"13","author":"Dorsch","year":"2012","journal-title":"BMC Nephrol"},{"key":"2021060310392973300_sfaa057-B25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000479390","article-title":"Practical value of anti-Xa activity in the evaluation of extracorporeal circuit anticoagulation during haemodialysis: results of a cross-sectional single-centre study","volume":"137","author":"Coene","year":"2017","journal-title":"Nephron"},{"key":"2021060310392973300_sfaa057-B26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/nep.13122","article-title":"Correlation between activated partial thromboplastin time and anti-Xa activity in patients who received low-molecular weight heparin as anticoagulation for haemodialysis","volume":"22","author":"Wong","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"2021060310392973300_sfaa057-B27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1076029617741363","article-title":"Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms","volume":"24","author":"Whitman-Purves","year":"2018","journal-title":"Clin Appl THromb Hemost"},{"key":"2021060310392973300_sfaa057-B28","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/ndt\/14.11.2698","article-title":"Comparison of low-molecular- weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation","volume":"14","author":"Saltissi","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"2021060310392973300_sfaa057-B29","doi-asserted-by":"crossref","first-page":"205435811880910","DOI":"10.1177\/2054358118809104","article-title":"An adjustable dalteparin sodium dose regimen for the prevention of clotting in the extracorporeal circuit in hemodialysis: a clinical trial of safety and efficacy (the PARROT study)","volume":"5","author":"Soroka","year":"2018","journal-title":"Can J Kidney Health Dis"},{"key":"2021060310392973300_sfaa057-B30","doi-asserted-by":"crossref","first-page":"e0128634","DOI":"10.1371\/journal.pone.0128634","article-title":"Where and when to inject low molecular weight heparin in hemodiafiltration? A cross over randomised trial","volume":"10","author":"Dhont","year":"2015","journal-title":"PLoS One"},{"key":"2021060310392973300_sfaa057-B31","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/nep.12681","article-title":"Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracoporeal blood circuit of patients on haemodialysis or haemodiafiltration: a randomized cross-over trial","volume":"21","author":"Kurtkoti","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"2021060310392973300_sfaa057-B32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12882-019-1527-3","article-title":"Renal Association Clinical Practice Guideline on haemodialysis","volume":"20","author":"Ashby","year":"2019","journal-title":"BMC Nephrol"},{"key":"2021060310392973300_sfaa057-B33","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/ndt\/gfm022","article-title":"EBPG guideline on dialysis strategies","volume":"22","author":"Tattersall","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2021060310392973300_sfaa057-B34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2015.07.015","article-title":"KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update","volume":"66","author":"Daugirdas","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2021060310392973300_sfaa057-B35","doi-asserted-by":"crossref","first-page":"c241","DOI":"10.1159\/000328072","article-title":"Renal Association Clinical Practice Guideline on haemodialysis","volume":"118","author":"Mactier","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"2021060310392973300_sfaa057-B36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/ndt\/gft508","article-title":"Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin","volume":"29","author":"Pauwels","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2021060310392973300_sfaa057-B37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MBC.0b013e32831bec0f","article-title":"Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens","volume":"20","author":"Sabry","year":"2009","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/4\/1120\/38462557\/sfaa057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/4\/1120\/38462557\/sfaa057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T13:05:59Z","timestamp":1622725559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/4\/1120\/5860799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,6,22]]},"published-print":{"date-parts":[[2021,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa057","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,6,22]]}}}